Quoin Pharmaceuticals (Quoin Pharmaceuticals) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Quoin Pharmaceuticals Debt-to-Equity?

Quoin Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Quoin Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Quoin Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $9.13 Mil. Quoin Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Quoin Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

During the past 5 years, the highest Debt-to-Equity Ratio of Quoin Pharmaceuticals was -0.18. The lowest was -0.42. And the median was -0.38.

QNRX's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

Quoin Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Quoin Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quoin Pharmaceuticals Debt-to-Equity Chart

Quoin Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

N/A

-0.18

Quoin Pharmaceuticals Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Quoin Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Quoin Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quoin Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Quoin Pharmaceuticals's Debt-to-Equity falls into.

Quoin Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Quoin Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	5.664
	=	0.00

Quoin Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	9.126
	=	0.00

Quoin Pharmaceuticals (NAS:QNRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Quoin Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Quoin Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quoin Pharmaceuticals Ltd (NAS:QNRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349

Website

https://www.quoinpharma.com

Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Executives

Dennis Langer	director	C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Michael T Sember	director	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101
Joseph Patrick Cooper	director	PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103
Anthony James Culverwell	director	C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Gordon Dunn	officer: Chief Financial Officer	AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101
Denise P. Carter	director, officer: Chief Operating Officer	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101
Leong Natalie Ee Mun	director	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Michael Myers	director, officer: Chief Executive Officer	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101